Clopidogrel in acute coronary syndrome: implications of recent study findings

References

• Lerberghe WV, Evans T, Rasanathan K, Mechbal A. The World Health Report 2008: Primary Health Care Now More Than Ever. WHO, Geneva, Switzerland (2008).
   Google Scholar
• Davi G, Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med.357(24), 2482–2494 (2007).
   PubMed Web of Science ®Google Scholar
• Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J.28(13), 1598–1660 (2007).
   PubMed Web of Science ®Google Scholar
• Kushner FG, Hand M, Smith SC Jr. et al. 2009 Focused Updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation120(22), 2271–2306 (2009).
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation116(7), e148–e304 (2007).
   PubMed Web of Science ®Google Scholar
• Collet JP, Montalescot G. P2Y12 inhibitors: thienopyridines and direct oral inhibitors. Hamostaseologie29(4), 339–348 (2009).
   PubMed Web of Science ®Google Scholar
• Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler. Thromb. Vasc. Biol.27(4), 728–739 (2007).
   PubMed Web of Science ®Google Scholar
• Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell84(2), 289–297 (1996).
   PubMed Web of Science ®Google Scholar
• Reininger AJ, Bernlochner I, Penz SM et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J. Am. Coll. Cardiol.55(11), 1147–1158 (2010).
   PubMed Web of Science ®Google Scholar
• Bergmeier W, Piffath CL, Goerge T et al. The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc. Natl Acad. Sci. USA103(45), 16900–16905 (2006).
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Brakebusch C, Bergmeier W et al. Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen. EMBO J.20(9), 2120–2130 (2001).
   PubMed Web of Science ®Google Scholar
• Nesbitt WS, Westein E, Tovar-Lopez FJ et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat. Med.15(6), 665–673 (2009).
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood108(6), 1903–1910 (2006).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation121(4), 569–583 (2010).
   PubMed Web of Science ®Google Scholar
• Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat. Clin. Pract. Cardiovasc. Med.5(12), 766–780 (2008).
   PubMedGoogle Scholar
• Stefanini L, Roden RC, Bergmeier W. CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood114(12), 2506–2514 (2009).
   PubMed Web of Science ®Google Scholar
• Cifuni SM, Wagner DD, Bergmeier W. CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin aIIbb3 in platelets. Blood112(5), 1696–1703 (2008).
   PubMed Web of Science ®Google Scholar
• Crittenden JR, Bergmeier W, Zhang Y et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat. Med.10(9), 982–986 (2004).
   PubMed Web of Science ®Google Scholar
• Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, Fischer TH, White GC 2nd. Rap1b is required for normal platelet function and hemostasis in mice. J. Clin. Invest.115(3), 680–687 (2005).
   PubMed Web of Science ®Google Scholar
• McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb. Res.95(1), 1–18 (1999).
   PubMed Web of Science ®Google Scholar
• Gachet C, Leon C, Hechler B. The platelet P2 receptors in arterial thrombosis. Blood Cells Mol. Dis.36(2), 223–227 (2006).
   PubMedGoogle Scholar
• Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem.273(4), 2030–2034 (1998).
   PubMed Web of Science ®Google Scholar
• Leon C, Hechler B, Freund M et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J. Clin. Invest.104(12), 1731–1737 (1999).
   PubMed Web of Science ®Google Scholar
• Kauffenstein G, Bergmeier W, Eckly A et al. The P2Y(12) receptor induces platelet aggregation through weak activation of the a(IIb)b(3) integrin – a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett.505(2), 281–290 (2001).
   PubMed Web of Science ®Google Scholar
• Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin. Vasc. Med.3(2), 113–122 (2003).
   PubMedGoogle Scholar
• CAPRIE-Steering-Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet348(9038), 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366(9497), 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med.354(16), 1706–1717 (2006).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Kim B, Zakarija A et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J. Am. Coll. Cardiol.50(12), 1138–1143 (2007).
   PubMed Web of Science ®Google Scholar
• Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur. Heart J.30(16), 1964–1977 (2009).
   PubMed Web of Science ®Google Scholar
• Lins R, Broekhuysen J, Necciari J, Deroubaix X. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin. Thromb. Hemost.25(Suppl. 2), 29–33 (1999).
   PubMed Web of Science ®Google Scholar
• Rehmel JL, Eckstein JA, Farid NA et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab. Dispos.34(4), 600–607 (2006).
   PubMed Web of Science ®Google Scholar
• Kuliczkowski W, Witkowski A, Polonski L et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J.30(4), 426–435 (2009).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation107(23), 2908–2913 (2003).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation116(25), 2923–2932 (2007).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Varenhorst C, James S et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J.29(1), 21–30 (2008).
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol.50(19), 1852–1856 (2007).
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med.360(4), 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360(4), 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet373(9660), 309–317 (2009).
   PubMed Web of Science ®Google Scholar
• Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet.41(12), 913–958 (2002).
   PubMed Web of Science ®Google Scholar
• Varenhorst C, James S, Erlinge D et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur. Heart J.30(14), 1744–1752 (2009).
   PubMed Web of Science ®Google Scholar
• King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, writing on behalf of the 2005 Writing Committee. Circulation117(2), 261–295 (2008).
   PubMed Web of Science ®Google Scholar
• McColl KE, Kennerley P. Proton pump inhibitors – differences emerge in hepatic metabolism. Dig. Liver Dis.34(7), 461–467 (2002).
   PubMedGoogle Scholar
• Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J. Am. Coll. Cardiol.51(3), 256–260 (2008).
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ180(7), 713–718 (2009).
   PubMed Web of Science ®Google Scholar
• Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol. Ther.31(8), 810–823 (2010).
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet374(9694), 989–997 (2009).
   PubMed Web of Science ®Google Scholar
• Caplain H, D’Honneur G, Cariou R. Prolonged heparin administration during clopidogrel treatment in healthy subjects. Semin. Thromb. Hemost.25(Suppl. 2), 61–64 (1999).
   PubMedGoogle Scholar
• Eikelboom JW, Hankey GJ, Thom J et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J. Thromb. Haemost.3(12), 2649–2655 (2005).
   PubMed Web of Science ®Google Scholar
• Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb. Haemost.103(3), 572–585 (2010).
   PubMed Web of Science ®Google Scholar
• Sibbing D, von Beckerath N, Morath T et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur. Heart J.31(10), 1205–1211 (2010).
   PubMed Web of Science ®Google Scholar
• Neubauer H, Mugge A. Thienopyridines and statins: assessing a potential drug–drug interaction. Curr. Pharm. Des.12(10), 1271–1280 (2006).
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart96(3), 186–189 (2010).
   PubMed Web of Science ®Google Scholar
• Diehl P, Olivier C, Halscheid C et al. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res. Cardiol.105(3), 379–387 (2010).
   PubMed Web of Science ®Google Scholar
• Bonello-Palot N, Armero S, Paganelli F et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am. J. Cardiol.104(11), 1511–1515 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes54(8), 2430–2435 (2005).
   PubMed Web of Science ®Google Scholar
• Geisler T, Grass D, Bigalke B et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J. Thromb. Haemost.6(1), 54–61 (2008).
   PubMed Web of Science ®Google Scholar
• Neubauer H, Kruger JC, Lask S et al. Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin. Res. Cardiol.98(9), 533–540 (2009).
   PubMedGoogle Scholar
• Kim SD, Kang W, Lee HW et al. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Clin. Ther.31(4), 793–803 (2009).
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation102(6), 624–629 (2000).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet358(9281), 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA294(10), 1224–1232 (2005).
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Steinhubl SR, Bhatt DL et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am. J. Cardiol.103(10), 1359–1363 (2009).
   PubMed Web of Science ®Google Scholar
• Berger JS, Bhatt DL, Cannon CP et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J. Am. Coll. Cardiol.54(21), 1935–1945 (2009).
   PubMed Web of Science ®Google Scholar
• Ahrens I, Bode C. Novel antiplatelet therapies following percutaneous coronary interventions. Curr. Opin. Investig. Drugs10(9), 902–911 (2009).
   Google Scholar
• Kimura T, Morimoto T, Nakagawa Y et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation119(7), 987–995 (2009).
   PubMed Web of Science ®Google Scholar
• Airoldi F, Colombo A, Morici N et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation116(7), 745–754 (2007).
   PubMed Web of Science ®Google Scholar
• Park SJ, Park DW, Kim YH et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N. Engl. J. Med.362(15), 1374–1382 (2010).
   PubMed Web of Science ®Google Scholar
• von Beckerath N, Taubert D, Pogatsa-Murray G et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation112(19), 2946–2950 (2005).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Costa MA, Shoemaker SB et al. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am. J. Cardiol.101(4), 440–445 (2008).
   PubMed Web of Science ®Google Scholar
• Aleil B, Jacquemin L, De Poli F et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc. Interv.1(6), 631–638 (2008).
   PubMedGoogle Scholar
• Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb. Res.121(4), 463–468 (2008).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation115(6), 708–716 (2007).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Bassand JP, Chrolavicius S et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am. Heart J.156(6), 1080–1088.e1 (2008).
   PubMed Web of Science ®Google Scholar
• Mehta SR. CURRENT-OASIS 7: a 2×2 factorial, randomized, trial of optimal clopidogrel and aspirin dosing in patients with ACS undergoing an early invasive strategy with intent for PCI. Presented at: European Society of Cardiology 2009 Congress. Barcelona, Spain, 30 August–2 September 2009.
   Google Scholar
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J.324(7329), 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Peters RJ, Mehta SR, Fox KA et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study. Circulation108(14), 1682–1687 (2003).
   PubMed Web of Science ®Google Scholar
• Fox KA, Steg PG, Eagle KA et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. JAMA297(17), 1892–1900 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357(20), 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation118(16), 1626–1636 (2008).
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet373(9665), 723–731 (2009).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K et al. Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. The RESPOND Study. Circulation121(10), 1188–1199 (2010).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet375(9711), 283–293 (2010).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM et al. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med.361(24), 2330–2341 (2009).
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med.361(24), 2318–2329 (2009).
   PubMed Web of Science ®Google Scholar
• Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler. Suppl.6(4), 3–11 (2005).
   PubMed Web of Science ®Google Scholar
• Jeong YH, Hwang JY, Kim IS et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ. Cardiovasc. Interv.3(1), 17–26 (2010).
   PubMed Web of Science ®Google Scholar
• Jeong YH, Lee SW, Choi BR et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J. Am. Coll. Cardiol.53(13), 1101–1109 (2009).
   PubMed Web of Science ®Google Scholar
• Chen KY, Rha SW, Li YJ et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation119(25), 3207–3214 (2009).
   PubMed Web of Science ®Google Scholar
• Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet367(9523), 1665–1673 (2006).
   PubMed Web of Science ®Google Scholar
• Walther DJ, Peter JU, Winter S et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet α-granule release. Cell115(7), 851–862 (2003).
   PubMed Web of Science ®Google Scholar
• Duerschmied D, Bode C. The role of serotonin in haemostasis. Hamostaseologie29(4), 356–359 (2009).
   Google Scholar
• Golino P, Piscione F, Willerson JT et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med.324(10), 641–648 (1991).
   PubMed Web of Science ®Google Scholar
• Duerschmied D, Canault M, Lievens D et al. Serotonin stimulates platelet receptor shedding by tumor necrosis factor-α-converting enzyme (ADAM17). J. Thromb. Haemost.7(7), 1163–1171 (2009).
   PubMed Web of Science ®Google Scholar
• Adams JW, Ramirez J, Shi Y et al. APD791, 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. J. Pharmacol. Exp. Ther.331(1), 96–103 (2009).
   PubMed Web of Science ®Google Scholar
• Przyklenk K, Frelinger AL 3rd, Linden MD et al. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J. Thromb. Haemost.8(2), 331–340 (2010).
   PubMed Web of Science ®Google Scholar
• Nishihira K, Yamashita A, Tanaka N et al. Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J. Thromb. Haemost.4(1), 247–255 (2006).
   PubMed Web of Science ®Google Scholar
• Fujita M, Mizuno K, Ho M et al. Sarpogrelate treatment reduces restenosis after coronary stenting. Am. Heart J.145(3), E16 (2003).
   PubMedGoogle Scholar
• Shinohara Y, Nishimaru K, Sawada T et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial. Stroke39(6), 1827–1833 (2008).
   PubMed Web of Science ®Google Scholar
• Diener JL, Daniel Lagasse HA, Duerschmied D et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J. Thromb. Haemost.7(7), 1155–1162 (2009).
   PubMed Web of Science ®Google Scholar
• Gilbert JC, DeFeo-Fraulini T, Hutabarat RM et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation116(23), 2678–2686 (2007).
   PubMed Web of Science ®Google Scholar
• Spiel AO, Mayr FB, Ladani N et al. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets20(5), 334–340 (2009).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br. J. Pharmacol.159(3), 502–517 (2009).
   PubMed Web of Science ®Google Scholar
• Vilahur G, Casani L, Badimon L. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb. Haemost.98(3), 662–669 (2007).
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin. Thromb. Hemost.35(2), 158–167 (2009).
   PubMed Web of Science ®Google Scholar
• Lages B, Weiss HJ. Biphasic aggregation responses to ADP and epinephrine in some storage pool deficient platelets: relationship to the role of endogenous ADP in platelet aggregation and secretion. Thromb. Haemost.43(2), 147–153 (1980).
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation119(2), 237–242 (2009).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Morath T et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol.53(10), 849–856 (2009).
   PubMed Web of Science ®Google Scholar
• Mueller T, Dieplinger B, Poelz W, Calatzis A, Haltmayer M. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer – comparison with two flow cytometric methods. Thromb. Res.121(2), 249–258 (2007).
   PubMed Web of Science ®Google Scholar
• Diehl P, Olivier C, Halscheid C et al. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y(12) expressing leukocytes. Basic Res. Cardiol.105(3), 379–387 (2010).
   PubMed Web of Science ®Google Scholar
• Michelson AD. Platelet function testing in cardiovascular diseases. Circulation110(19), e489–e493 (2004).
   Google Scholar
• Minamino T, Kitakaze M, Sanada S et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation98(17), 1721–1727 (1998).
   PubMed Web of Science ®Google Scholar
• Aleil B, Ravanat C, Cazenave JP et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J. Thromb. Haemost.3(1), 85–92 (2005).
   PubMed Web of Science ®Google Scholar
• Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J. Am. Coll. Cardiol.46(9), 1705–1709 (2005).
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA303(8), 754–762 (2010).
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol.48(9), 1742–1750 (2006).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Jawansky S et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb. Haemost.99(1), 121–126 (2008).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Christ G, Lang IM et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J. Thromb. Haemost.8(2), 351–359 (2010).
   PubMed Web of Science ®Google Scholar
• Fox SC, Behan MW, Heptinstall S. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium35(1), 39–46 (2004).
   PubMed Web of Science ®Google Scholar
• Madsen EH, Saw J, Kristensen SR et al. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin. Chem.56(5), 839–847 (2010).
   Google Scholar
• Barragan P, Bouvier JL, Roquebert PO et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter. Cardiovasc. Interv.59(3), 295–302 (2003).
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Quilici J et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb. Haemost.98(4), 838–843 (2007).
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol.51(14), 1404–1411 (2008).
   PubMed Web of Science ®Google Scholar